Fazirsiran for Adults with Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA)

By sjmartinez • July 5, 2024

Clark VC, Strange C, Strnad P, Sanchez AJ, Kwo P, Pereira VM, van Hoek B, Barjaktarevic I, Corsico AG, Pons M, Goldklang M, Gray M, Kuhn B, Vargas HE, Vierling JM, Vuppalanchi R, Brantly M, Kappe N, Chang T, Schluep T, Zhou R, Hamilton J, San Martin J, Loomba R. Fazirsiran for Adults with Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA). Gastroenterology. 2024 Jul 2:S0016-5085(24)05181-3. doi: 10.1053/j.gastro.2024.06.028. Epub ahead of print. PMID: 38964420.

Tags: AAT, alpha-1 antitrypsin deficiency, Fazirsiran, Liver disease, Publications, Pulmonary, Critical Care & Sleep Medicine, Z-AAT

Prevalent Adverse Childhood Experiences Among Young Adults Returning Home From Jail: The Need for Trauma-Informed Reentry Services

Barnert E, Applegarth DM, Bondoc C, Biely C, Leifheit KM, Grella C, Wong MD. Prevalent Adverse Childhood Experiences Among Young Adults Returning Home From Jail:[...]

CD38 regulates chronic lymphocytic leukemia proliferation via CD45 phosphatase activity

Imbery JF, Wiik C, Heinzelbecker J, Jebsen JK, Dobbing MK, Bottini N, Stanford SM, Munthe LA, Tjønnfjord GE, Tveita A, Szodoray P, Nakken B. CD38[...]

Extracellular vesicles from human breast cancer-resistant cells promote acquired drug resistance and pro-inflammatory macrophage response

Santos P, Rezende CP, Piraine R, Oliveira B, Ferreira FB, Carvalho VS, Calado RT, Pellegrini M, Almeida F. Extracellular vesicles from human breast cancer-resistant cells[...]